Trial Profile
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Blepharoptosis
- Focus Registrational; Therapeutic Use
- Sponsors RevitaLid; RVL; RVL Pharmaceuticals
- 03 Apr 2023 According to a RVL Pharmaceuticals media release, company announced today that its prescription eye drop Upneeq, 0.1% has been selected winner in the professional treatment category as 'Best Eye Drop for Drooping Lids' in the NewBeauty 13th Annual Beauty Awards, which hits newsstand on 4 Apr, 2023. Also, previously,Upneeq was awarded the 'Best Innovation' in 2022 by this definitive authority in beauty.
- 01 Oct 2020 According to an Osmotica Pharmaceutical media release, Charles Slonim is the lead medical monitor for this study.
- 01 Oct 2020 Pooled analysis from two Phase 3 studies (Study RVL-1201-201 and Study RVL-1201-202) published in the Osmotica Pharmaceutical Media Release.